121 related articles for article (PubMed ID: 2332079)
1. [Comprehensive approach to clinical background and effect of bromocriptine administration in patients with endocrinological polycystic ovarian disease].
Aisaka K; Kaneda S; Tsuzuki H; Tawada T; Kokuho K; Toriya Y; Nojima M; Yoshida K; Mori H
Nihon Naibunpi Gakkai Zasshi; 1990 Feb; 66(2):101-12. PubMed ID: 2332079
[TBL] [Abstract][Full Text] [Related]
2. Recovery of hormone secretion after chronic gonadotropin-releasing hormone agonist administration in women with polycystic ovarian disease.
de Ziegler D; Steingold K; Cedars M; Lu JK; Meldrum DR; Judd HL; Chang RJ
J Clin Endocrinol Metab; 1989 Jun; 68(6):1111-7. PubMed ID: 2524501
[TBL] [Abstract][Full Text] [Related]
3. Acute effects of bromocriptine on gonadotropin secretion in polycystic ovary syndrome.
Buvat J; Buvat-Herbaut M; Marcolin G; Racadot A; Fourlinnie JC; Fossati P
Fertil Steril; 1985 Sep; 44(3):356-60. PubMed ID: 3161758
[TBL] [Abstract][Full Text] [Related]
4. The effect of bromocriptine on gonadotropin and steroid secretion in polycystic ovarian disease.
Steingold KA; Lobo RA; Judd HL; Lu JK; Chang RJ
J Clin Endocrinol Metab; 1986 May; 62(5):1048-51. PubMed ID: 2937800
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of ovulation by progestin analogs (agonists vs antagonists): preliminary evidence for different sites and mechanisms of actions.
Heikinheimo O; Gordon K; Williams RF; Hodgen GD
Contraception; 1996 Jan; 53(1):55-64. PubMed ID: 8631191
[TBL] [Abstract][Full Text] [Related]
6. The effects of ovarian wedge resection on circulating gonadotropin and ovarian steroid levels in patients with polycystic ovary syndrome.
Judd HL; Rigg LA; Anderson DC; Yen SS
J Clin Endocrinol Metab; 1976 Aug; 43(2):347-55. PubMed ID: 950366
[TBL] [Abstract][Full Text] [Related]
7. [Effects of bromocriptine on endocrine environment in the polycystic ovary syndrome].
Huang HJ; Ishimaru T; Yamabe T
Nihon Naibunpi Gakkai Zasshi; 1988 Apr; 64(4):265-78. PubMed ID: 3136040
[TBL] [Abstract][Full Text] [Related]
8. Bromocriptine in polycystic ovarian disease: a controlled clinical trial.
el Tabbakh GH; Loutfi IA; Azab I; Rahman HA; Southren AL; Aleem FA
Obstet Gynecol; 1988 Mar; 71(3 Pt 1):301-6. PubMed ID: 3279350
[TBL] [Abstract][Full Text] [Related]
9. A double blind controlled study of the hormonal and clinical effects of bromocriptine in the polycystic ovary syndrome.
Buvat J; Buvat-Herbaut M; Marcolin G; Racadot A; Fourlinnie JC; Beuscart R; Fossati P
J Clin Endocrinol Metab; 1986 Jul; 63(1):119-24. PubMed ID: 3519644
[TBL] [Abstract][Full Text] [Related]
10. Effect of bromocriptine on LH pulsatility in the polycystic ovary syndrome.
Chapman AJ; Wilson MD; Obhrai M; Sawers RS; Lynch SS; Royston JP; Clayton RN
Clin Endocrinol (Oxf); 1987 Nov; 27(5):571-80. PubMed ID: 3450455
[TBL] [Abstract][Full Text] [Related]
11. The relationship between serum anti-Müllerian hormone levels and the follicular arrest for women with polycystic ovary syndrome.
Li J; Li R; Yu H; Zhao S; Yu Y; Qiao J
Syst Biol Reprod Med; 2015 Apr; 61(2):103-9. PubMed ID: 25329139
[TBL] [Abstract][Full Text] [Related]
12. The impact of obesity and chronic hyperinsulinemia on gonadotropin release and gonadal steroid secretion in the polycystic ovary syndrome.
Dunaif A; Mandeli J; Fluhr H; Dobrjansky A
J Clin Endocrinol Metab; 1988 Jan; 66(1):131-9. PubMed ID: 2961783
[TBL] [Abstract][Full Text] [Related]
13. Gonadotropin-releasing hormone (GnRH) analog suppression renders polycystic ovarian disease patients more susceptible to ovulation induction with pulsatile GnRH.
Filicori M; Campaniello E; Michelacci L; Pareschi A; Ferrari P; Bolelli G; Flamigni C
J Clin Endocrinol Metab; 1988 Feb; 66(2):327-33. PubMed ID: 3123511
[TBL] [Abstract][Full Text] [Related]
14. Hormone levels following wedge resection in polycystic ovary syndrome.
Mahesh VB; Toledo SP; Mattar E
Obstet Gynecol; 1978 Jan; 51(1 Suppl):64s-69s. PubMed ID: 144874
[TBL] [Abstract][Full Text] [Related]
15. Serum bioactive and immunoreactive luteinizing hormone and follicle-stimulating hormone levels in women with cycle abnormalities, with or without polycystic ovarian disease.
Fauser BC; Pache TD; Lamberts SW; Hop WC; de Jong FH; Dahl KD
J Clin Endocrinol Metab; 1991 Oct; 73(4):811-7. PubMed ID: 1909705
[TBL] [Abstract][Full Text] [Related]
16. [A longitudinal study on the prognosis of ovulatory disturbance in teenage patients with high LH and normal FSH serum levels].
Kimura K; Minakami H; Tamada T
Nihon Naibunpi Gakkai Zasshi; 1988 Oct; 64(10):1088-101. PubMed ID: 3145220
[TBL] [Abstract][Full Text] [Related]
17. [The effects of bromocriptine on anovulatory patients with high LH and euprolactinemia].
Mori H; Aisaka K; Matsuoka R; Kigawa T
Nihon Naibunpi Gakkai Zasshi; 1985 Jan; 61(1):48-55. PubMed ID: 3922814
[TBL] [Abstract][Full Text] [Related]
18. [The effects of dopamine agonist (bromocriptine) on the secretion of pituitary gonadotropins and ovarian sex steroids in normally cycling women].
Aisaka K; Mori H; Ogawa T; Kigawa T
Nihon Naibunpi Gakkai Zasshi; 1984 Sep; 60(9):1067-79. PubMed ID: 6440815
[TBL] [Abstract][Full Text] [Related]
19. [Studies on prolactin secreting capacity in the ovulatory infertile patients with transient hyperprolactinemia].
Aisaka K; Ando S; Kokubo K; Yoshida K; Mori H
Nihon Naibunpi Gakkai Zasshi; 1986 May; 62(5):662-71. PubMed ID: 3089848
[TBL] [Abstract][Full Text] [Related]
20. [A possible role of ultrasound-guided follicular aspiration in induction of ovulation in patients with polycystic ovaries].
Katagiri C
Nihon Sanka Fujinka Gakkai Zasshi; 1994 May; 46(5):409-15. PubMed ID: 8182300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
